Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Leveraging our advanced platforms, Creative Biolabs provides full comprehensive, and high-quality CD38-targeted recombinant antibodies for clients around the world. We are committed to advancing research and discovery with exceptional value and unparalleled technical support, ensuring our clients achieve their scientific goals efficiently and effectively.
CD38 is a multifunctional ectoenzyme that plays a pivotal role in cellular signaling and immune responses. It facilitates the conversion of NAD+ to cyclic ADP-ribose (cADPR) and subsequently hydrolyzes cADPR to ADP-ribose. This enzyme becomes significantly upregulated during infections and inflammation, contributing to various inflammatory processes, transmembrane signaling, and cell adhesion. Due to its critical involvement in these mechanisms, CD38 is frequently used as a biomarker for inflammatory diseases such as leukemia and myeloma.
Cluster Of Differentiation 38; CD38 molecule; CD38 Antigen; ADPRC1; ADP-Ribosyl Cyclase 1; Cyclic ADP-Ribose Hydrolase 1; 2-Phospho-ADP-Ribosyl Cyclase; Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase; NAD(+) Nucleosidase; 2-Phospho-Cyclic-ADP-Ribose Transferase; CADPr Hydrolase 1; T10
Our mission is to boost research and innovation by offering premium anti-CD38 recombinant antibodies at exceptional value, coupled with top-notch technical support. The list below contains several anti-CD38 recombinant antibodies. For more information and to select the best option, please visit the link.
Cat. No. | Product Name | Target Species | Host Species | Applications |
HPAB-0301-YC | Human Anti-CD38 Recombinant Antibody | Human, Cynomolgus | Human IgG1 | ELISA, FC, Cyt |
HPAB-0379-FY | Mouse Anti-CD38 Recombinant Antibody (clone OKT10) | Human | Mouse IgG | Cyt, Block, Activ |
HPAB-0470LY | Mouse Anti-CD38 Recombinant Antibody (clone S5B5) | Human | Mouse IgG | ELISA, Block |
HPAB-0134CQ | Human Anti-CD38 Recombinant Antibody | Human | Human IgG1, λ | ELISA, FC, ADCC, FuncS |
TAB-154LC | Human Anti-CD38 Recombinant Antibody | Cynomolgus, Human | Human IgG1 | ELISA, FC, IF, FuncS |
Our commitment is to empower the biopharmaceutical community by advancing research and development through unparalleled product quality and exceptional support. We prioritize customer satisfaction by rigorously maintaining a comprehensive quality management system. This ensures our products not only meet but surpass industry standards, thereby streamlining the drug development process and delivering superior value to our customers.
Fig.1 Anti-CD38 Recombinant Antibody in WB.
(Cat# HPAB-0134CQ, Creative Biolabs).
Fig.2 Anti-CD38 Recombinant Antibody in ELISA.
(Cat# HPAB-0134CQ, Creative Biolabs).
Fig.3 Anti-CD38 Therapeutic Antibody in SDS-PAGE.
(Cat# HPAB-0134CQ. Creative Biolabs).
Fig.4 Anti-CD38 Recombinant Antibody in HPLC.
(Cat# HPAB-0379-FY, Creative Biolabs).
Fig.5 Recombinant Anti-CD38 Antibody in SDS-PAGE.
(Cat# HPAB-0301-YC, Creative Biolabs).
Fig.6 Recombinant Anti-CD38 Antibody Phycoerythrin Label Assay.
(Cat# HPAB-0301-YC, Creative Biolabs).
Our cutting-edge serum-free mammalian cell expression platform offers comprehensive services from gene synthesis to scalable, high-quality anti-CD38 recombinant antibody production. With over 5 years of expertise and experience in process optimization, we deliver fast and cost-effective solutions for rapid various quantities of antibody supply in a short turnaround.
Featured Anti-CD38 Recombinant Antibody Production Platforms
Fig.7 Milligram-scale anti-CD38 recombinant antibody production.
Fig.8 Gram-scale anti-CD38 recombinant antibody production.
Creative Biolabs is dedicated to delivering highly innovative and diverse recombinant antibodies to researchers. Our anti-CD38 recombinant antibodies include various formats such as full-length, Fab, scFv, etc. Leveraging our extensive expertise and experience in antibody engineering, we have the confidence and capacity to provide customized solutions to meet your specific research needs.
Fig.9 Full-Length Anti-CD38 Recombinant Antibody Production and Modalities.
Table 1. CD38-targeted drug information.
Company | Research Phase | Condition | Indication |
Janssen Pharmaceutical (JP) | Launched - 2017 | Multiple myeloma | Treatment of adults with relapsed or refractory multiple myeloma in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone; In combination with carfilzomib and dexamethasone, for the treatment of patients with recurrent or refractory multiple myeloma |
Janssen | Registered - 2018 | Multiple myeloma | In combination with bortezomib, melphalan and prednisone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT) |
Janssen | Phase III | Multiple myeloma | Treatment of pediatric and adult patients with multiple myeloma as monotherapy or in combination with carfilzomib, dexamethasone, lenalidomide and pomalidomide |
Mayo Clinic | Phase II | Glomerulonephritis, membranoproliferative | Treatment of proliferative glomerulonephritis with monoclonal immune deposits and C3 glomerulopathy associated with monoclonal gammopathy |
Janssen Pharmaceutical (JP) | Launched - 2021 | Light chain amyloidosis | In patients with newly diagnosed light-chain (AL) amyloidosis, in combination with cyclophosphamide, bortezomib and dexamethasone |
Sanofi | Launched - 2020 | Multiple myeloma | Treatment of recurrent or refractory multiple myeloma, in combination with pomalidomide and dexamethasone |
Sanofi | Registered - 2020 | Multiple myeloma | Treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy, in combination with pomalidomide and dexamethasone; In combination with carfilzomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy |
Sanofi | Pre-Registered | Multiple myeloma | In combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) |
Biocad | Phase III | Multiple myeloma | As monotherapy in adults with relapsed and refractory multiple myeloma |
I-Mab Biopharma | Phase III | Multiple myeloma | In patients with relapsed/refractory multiple myeloma who have received at least one prior line of therapy, in combination with lenalidomide and dexamethasone |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Please contact us to learn more about our anti-CD38 recombinant antibody products. We are eager to explore opportunities for a mutually beneficial collaboration and help you advance your research.